{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:02:50Z","timestamp":1791547370830,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijantimicag.2023.106880","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T22:09:13Z","timestamp":1686262153000},"page":"106880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia"],"prefix":"10.1016","volume":"62","author":[{"given":"Luyao","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106880_bib0001","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13613-022-01033-5","article-title":"Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case\u2013control study","volume":"12","author":"Liu","year":"2022","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0002","first-page":"347","article-title":"New guidelines for hospital-acquired pneumonia\/ventilator-associated pneumonia: USA vs. Europe","volume":"24","author":"Martin-Loeches","year":"2018","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0003","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 7","key":"10.1016\/j.ijantimicag.2023.106880_bib0004","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0006","article-title":"Polymyxins bind to the cell surface of unculturable Acinetobacter baumannii and cause unique dependent resistance","volume":"7","author":"Zhu","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0008","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/antibiotics8020042","article-title":"Shifting gears: the future of polymyxin antibiotics","volume":"8","author":"Lenhard","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-3-030-16373-0_18","article-title":"Mechanisms of polymyxin-induced nephrotoxicity","volume":"1145","author":"Azad","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0012","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00152-21","article-title":"Combined effect of polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant Klebsiella pneumoniae","volume":"9","author":"Tian","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0014","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijantimicag.2017.02.025","article-title":"Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention","volume":"50","author":"Biffi","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0016","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1248\/bpb.b13-00109","article-title":"Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii","volume":"37","author":"Kwon","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0017","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2014.12.018","article-title":"Cefepime free minimum concentration to minimum inhibitory concentration (fCmin\/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia","volume":"45","author":"Aitken","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0018","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41564-018-0342-0","article-title":"The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification","volume":"4","author":"Nicoloff","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0019","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1093\/jac\/dkw293","article-title":"Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies","volume":"71","author":"Rao","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijantimicag.2016.06.006","article-title":"Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii","volume":"48","author":"Rao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0021","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jgar.2020.12.026","article-title":"Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: an evaluation of the current evidence","volume":"24","author":"Falagas","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0023","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/jac\/dkv340","article-title":"Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins","volume":"71","author":"Lu","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0024","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.2147\/IDR.S332160","article-title":"Sulbactam enhances in vitro activity of \u03b2-lactam antibiotics against Acinetobacter baumannii","volume":"14","author":"Wang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106271","article-title":"Enhanced bacterial killing with colistin\/sulbactam combination against carbapenem-resistant Acinetobacter baumannii","volume":"57","author":"Bian","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0026","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/mdr.2019.0088","article-title":"Synergistic activities of colistin combinations with meropenem, sulbactam, minocycline, disodium fosfomycin, or vancomycin against different clones of carbapenem-resistant Acinetobacter baumannii strains","volume":"26","author":"Sertcelik","year":"2020","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0028","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fphar.2019.00754","article-title":"Comparative metabolomics reveals key pathways associated with the synergistic killing of colistin and sulbactam combination against multidrug-resistant Acinetobacter baumannii","volume":"10","author":"Han","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0029","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1128\/AAC.01624-13","article-title":"In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii","volume":"58","author":"Hagihara","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0030","doi-asserted-by":"crossref","first-page":"e18485","DOI":"10.1371\/journal.pone.0018485","article-title":"In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore","volume":"6","author":"Lim","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0031","article-title":"Polymyxin B\/tigecycline combination vs. polymyxin B or tigecycline alone for the treatment of hospital-acquired pneumonia caused by carbapenem-resistant Enterobacteriaceae or carbapenem-resistant Acinetobacter baumannii","volume":"9","author":"Chang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0032","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0033","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000445425","article-title":"Efficacy and safety of tigecycline for patients with hospital-acquired pneumonia","volume":"61","author":"Xu","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106487","article-title":"Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia","volume":"59","author":"Dimopoulos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0035","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkp301","article-title":"Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs","volume":"64","author":"Crandon","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106344","article-title":"Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli","volume":"57","author":"Scudeller","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0037","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/jac\/dkw355","article-title":"High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii","volume":"72","author":"Lenhard","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0038","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jgar.2021.01.018","article-title":"What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB)? A multicentre study in Korea","volume":"24","author":"Seok","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0039","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2147\/IDR.S357746","article-title":"Polymyxin B-based regimens for patients infected with carbapenem-resistant Gram-negative bacteria: clinical and microbiological efficacy, mortality, and safety","volume":"15","author":"Qu","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105943","article-title":"Pharmacokinetic\/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations","volume":"55","author":"Xie","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0041","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijid.2022.01.055","article-title":"Risk factors for polymyxin B-associated acute kidney injury","volume":"117","author":"Chang","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2023.05.018","article-title":"A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalised patients","author":"Hanafin","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106880_bib0043","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2147\/DDDT.S313714","article-title":"Optimal empiric polymyxin B treatment of patients infected with Gram-negative organisms detected using a blood antimicrobial surveillance network in China","volume":"15","author":"Wu","year":"2021","journal-title":"Drug Des Devel Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:48:33Z","timestamp":1760377713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0924857923001590"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106880","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106880"}}